Apyx Medical Corporation cash flow to debt ratio of -20.34% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Apyx Medical Corporation's free cash flow has increased -51.44% from $-18.77M last year to $-9.12M, signaling increasing performance

Apyx Medical Corporation's debt to equity ratio is 3.08, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Apyx Medical Corporation's debt has increased relative to shareholder equity from 2.73 last year to 3.08 today, signaling weakened financials

Apyx Medical Corporation has negative EBITDA, making leverage ratio unreliable

Apyx Medical Corporation's interest coverage ratio is -0.77, which means that the company struggles to meet interest obligations, signaling financial risk.

Apyx Medical Corporation's profit margin has increased (-66.38%) in the last year from -48.78% to -16.40%, signaling increasing performance

Apyx Medical Corporation's short-term assets of $58.47M exceed its short-term liabilities of $11.70M

Apyx Medical Corporation's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Apyx Medical Corporation's return on equity of -90.62%, is lower than 15.00%, indicating bad performance

Apyx Medical Corporation's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Apyx Medical Corporation had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Apyx Medical Corporation has negative free cash flow, indicating the company is burning cash rather than generating it

Apyx Medical Corporation has negative free cash flow, indicating cash burn

Apyx Medical Corporation's yearly earnings has increased -52.22% since last year from $-23.46M to $-11.21M, signaling increasing performance

Apyx Medical Corporation's yearly revenue has increased 9.86% since last year from $48.10M to $52.84M, signaling increasing performance

ROIC -7.97% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Apyx Medical Corporation's 3-year revenue CAGR of 5.89% is positive, indicating growing revenue over the past 3 years

Apyx Medical Corporation had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Apyx Medical Corporation had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Apyx Medical Corporation has insufficient data to evaluate this check.

Apyx Medical Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Apyx Medical Corporation is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Apyx Medical Corporation has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Apyx Medical Corporation is overvalued relative to its fair value price of -8.00 based on Earnings Fair Value model

Apyx Medical Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Apyx Medical Corporation has a price-to-book ratio of 13.60x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Apyx Medical Corporation has a price-to-sales ratio of 3.18x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue